CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

Merck’s return to ophthalmology snags first success

KeytrudaPositive
AI Analysis

Summary

Merck's 2024 acquisition of EyeBio for $1.3 billion upfront is showing early commercial success as the company expands beyond its oncology franchise into ophthalmology.

Importance:6/10
Sentiment:
0.60
acquisitionophthalmologystrategic expansionEyeBio2024 deal
Related Companies

Read the original article

Published by Endpoints News on September 24, 2026 12:14 PM

Read Original